



ATTORNEY DOCKET NUMBER: 2002834-0058 (CIP4 DIV/Modified Allergens)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bannon, et al.
Serial No.: 09/478,668
Filed: January 6, 2000
For: METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS
TO ALLERGY

Examiner: Huynh, P.
Art Unit: 1644

Assistant Commissioner for Patents
Washington, DC 20231
BOX AF


TRANSMITTAL

Enclosed please find the following documents regarding the above-referenced matter:


1. Supplemental Response to Office Action (3 page);
2. Exhibits A-G; and
3. a Return Postcard.

Please charge any fees or credit any overpayments to our Deposit Account No. 03-1721.

Respectfully submitted,


Brenda Herschbach Jarrell, Ph.D.
Reg. No. 39,233

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Dated: September 17, 2002
3458528_1.DOC

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on 9/19/02


TECH CENTER 1600/2900

SEP 25 2002

RECEIVED

1644



RECEIVED

SEP 25 2002

TECH CENTER 1600/290L

ATTORNEY DOCKET NUMBER: 2002834-0058 (CIP4 DIV/Modified Allergens)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Bannon, et al.	Examiner:	Huynh, P.
Serial No.:	09/478,668	Art Unit:	1644
Filed:	January 6, 2000	Group:	1640
For:	METHODS AND REAGENTS FOR DECREASING CLINICAL REACTIONS TO ALLERGY		

Assistant Commissioner for Patents
Washington, DC 20231
BOX AF

SUPPLEMENTAL RESPONSE TO OFFICE ACTION

Sir:

In response to the Final Office Action mailed December 18, 2001, the Interview held June 19, 2002 and further to the Response mailed June 18, 2002, Applicant respectfully requests consideration of the following Remarks.

Remarks

Applicant's representatives, Drs. Brenda Jarrell and Charles Lyon, would like to take this opportunity to thank Examiners Huynh and Chan for taking the time to hold an in person Interview on June 19, 2002. During the Interview, the Examiners indicated that they would be willing to consider evidence in support of Applicant's enablement argument. In particular, they indicated that they would consider post-art references that showed that the methods taught in the present application have been successfully applied to other allergens.

Accordingly, Applicant has collected a series of references showing that, after the present invention was made, people of ordinary skill in the art followed the steps taught in the present application (i.e., used patient sera to identify IgE binding epitopes, modified the protein sequence to alter identified IgE binding epitopes; and screened modified proteins to identify those with reduced binding) and were able without undue experimentation to obtain a variety of modified

#19
JW
10/2/02